Language
English
Publication Date
9-12-2023
Journal
Blood Advances
DOI
10.1182/bloodadvances.2022007611
PMID
36322878
PMCID
PMC10463203
PubMedCentral® Posted Date
11-4-2022
PubMedCentral® Full Text Version
Post-print
Abstract
Chronic graft-versus-host disease (cGvHD) remains a prominent barrier to allogeneic hematopoietic stem cell transplantion as the leading cause of nonrelapse mortality and significant morbidity. Tremendous progress has been achieved in both the understanding of pathophysiology and the development of new therapies for cGvHD. Although our field has historically approached treatment from an empiric position, research performed at the bedside and bench has elucidated some of the complex pathophysiology of cGvHD. From the clinical perspective, there is significant variability of disease manifestations between individual patients, pointing to diverse biological underpinnings. Capitalizing on progress made to date, the field is now focused on establishing personalized approaches to treatment. The intent of this article is to concisely review recent knowledge gained and formulate a path toward patient-specific cGvHD therapy.
Keywords
Humans, Consensus, Precision Medicine, Graft vs Host Disease, Bronchiolitis Obliterans Syndrome, Biology
Published Open-Access
yes
Recommended Citation
Buxbaum, Nataliya P; Socié, Gerard; Hill, Geoffrey R; et al., "Chronic GvHD NIH Consensus Project Biology Task Force: Evolving Path to Personalized Treatment of Chronic GvHD" (2023). Faculty, Staff and Students Publications. 8138.
https://digitalcommons.library.tmc.edu/baylor_docs/8138